Medically reviewed by Jamin Brahmbhatt, MD IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system ...

With new immunoglobulin A (IgA) nephropathy data and therapies highlighted at the American Society of Nephrology Kidney Week meeting, understanding how to apply that information in real-world practice ...

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient ...

Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling ...

In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney’s filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways IgA nephropathy is diagnosed through a combination of clinical ...

- Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24 - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24 PASADENA, ...

If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...

The MarketWatch News Department was not involved in the creation of this content. -- PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of ...

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency ...